Selective high-affinity polydentate ligands and methods of making such

1. A selective high affinity ligand (SHAL) that specifically binds to a cancer cell expressing HLA-DR10, wherein said SHAL comprises the structure:

wherein R 1 is selected from the group consisting of COOH, a linker, an effector, and a linker attached to an effector, wherein:

when R 1 is a linker, the linker is polyethylene glycol, biotin, or lysine; and

when R 1 is an effector, the effector is selected from avidin, biotin, and a cytotoxin selected from the group of a Diphtheria toxin, a Pseudomonas exotoxin, a ricin, an abrin, and a thymidine kinase, a chelate comprising (a) a metal isotope selected from the group of 99 Tc, 203 Pb, 67 Ga, 68 Ga, 72 As, 111 In, 113m In, 97 Ru, 62 Cu, 64 Cu, 52 Fe, 52m Mn, 51 Cr, 186 Re, 188 Re, 77 As, 90 Y, 67 Cu, 169 Er, 121 Sn, 127 Te, 142 Pr, 143 Pr, 198 Au, 199 Au, 161 Tb, 109 Pd, 165 Dy, 149 Pm, 151 Pm, 153 Sm, 157 Gd, 159 Gd, 166 Ho, 172 Tm, 169 Yb, 175 Yb, 177 Lu, 105 Rh, and 111 Ag, (b) bismuth 213, or (c) DOTA, 4[[5-(Trifluoromethyl)pyridin-2-yl]oxy]phenyl]N-phenylcarbamate, (R)-2-[4-(5-chloro-3-fluoro-2-pyridyloxy)phenoxy]propionic acid, 2-(((3-chloro-5(trifluoromethyl)pyridin-2-yloxy)phenoxy)methyl)acrylates, 2-(((3-chloro-5(trifluoromethyl)pyridin-2-yloxy)phenyl)methyl)acrylates, 2-(((3-chloro-5(trifluoromethyl)pyridin-2-yloxy)phenyl)methyl)acrylonitriles, 3-(3-chloro-4-{[5-(trifluoromethyl)-2-pyridinyl]oxy}anilino)-3-oxopropanoic acid, Sethoxydim, Clethodim, 5-(Tetradecyloxy)-2-furoic acid, 2-[(2,6-Dichlorophenyl)amino]benzeneacetic acid, 2-[4-(4-Chlorophenoxy)phenoxy]propanoic acid, (RS)-2-{4-[3-chloro-5-(trifluoromethyl)-2-pyridinyl]oxy]phenoxy}propanoic acid, (RS)-2-[4-(6-chloro-1,3-benzoxazol-2-yloxy)phenoxy]propanoic acid, (RS)-2-[4-(2,4-dichlorophenoxy)phenoxy]propanoic acid, (RS)-2-{4-[5-(trifluoromethyl)-2-pyridyloxy]phenoxy}propanoic acid, (RS)-2-[4-(6-chloroquinoxalin-2-yloxy)phenoxy]propanoic acid, and (RS)-2-[4-(α,α,α-trifluoro-p-tolyloxy)phenoxy]propanoic acid.

2. The SHAL of claim 1 , wherein said SHAL comprises the structure:

wherein R 2 is selected from the group consisting of COOH, a linker, an effector, and a linker attached to an effector, wherein:

when R 2 is a linker, the linker is polyethylene glycol, biotin, or lysine; and

when R 1 is an effector, the effector is selected from avidin, biotin, and a cytotoxin selected from the group of a Diphtheria toxin, a Pseudomonas exotoxin, a ricin, an abrin, and a thymidine kinase, a chelate comprising (a) a metal isotope selected from the group of 99 Tc, 203 Pb, 67 Ga, 68 Ga, 72 As, 111 In, 113m In, 97 Ru, 62 Cu, 64 Cu, 52 Fe, 52m Mn, 51 Cr, 186 Re, 188 Re, 77 As, 90 Y, 67 Cu, 169 Er, 121 Sn, 127 Te, 142 Pr, 143 Pr, 198 Au, 199 Au, 161 Tb, 109 Pd, 165 Dy, 149 Pm, 151 Pm, 153 Sm, 157 Gd, 159 Gd, 166 Ho, 172 Tm, 169 Yb, 175 Yb, 177 Lu, 105 Rh, and 111 Ag, (b) bismuth 213, or (c) DOTA, 4[[5-(Trifluoromethyl)pyridin-2-yl]oxy]phenyl]N-phenylcarbamate, (R)-2-[4-(5-chloro-3-fluoro-2-pyridyloxy)phenoxy]propionic acid, 2-(((3-chloro-5(trifluoromethyl)pyridin-2-yloxy)phenoxy)methyl)acrylates, 2-(((3-chloro-5(trifluoromethyl)pyridin-2-yloxy)phenyl)methyl)acrylates, 2-(((3-chloro-5(trifluoromethyl)pyridin-2-yloxy)phenyl)methyl)acrylonitriles, 3-(3-chloro-4-{[5-(trifluoromethyl)-2-pyridinyl]oxy}anilino)-3-oxopropanoic acid, Sethoxydim, Clethodim, 5-(Tetradecyloxy)-2-furoic acid, 2-[(2,6-Dichlorophenyl)amino]benzeneacetic acid, 2-[4-(4-Chlorophenoxy)phenoxy]propanoic acid, (RS)-2-{4-[3-chloro-5-(trifluoromethyl)-2-pyridinyl]oxy]phenoxy}propanoic acid, (RS)-2-[4-(6-chloro-1,3-benzoxazol-2-yloxy)phenoxy]propanoic acid, (RS)-2-[4-(2,4-dichlorophenoxy)phenoxy]propanoic acid, (RS)-2-{4-[5-(trifluoromethyl)-2-pyridyloxy]phenoxy}propanoic acid, (RS)-2-[4-(6-chloroquinoxalin-2-yloxy)phenoxy]propanoic acid, and (RS)-2-[4-(α,α,α-trifluoro-p-tolyloxy)phenoxy]propanoic acid.

3. The SHAL according to claim 1 or 2 , wherein said SHAL is polyvalent or polyspecific.

4. The SHAL of claim 1 or 2 , wherein the SHAL has antilymphoma activity.

5. The SHAL of any one of claim 1 or 2 , wherein said linker is polyethylene glycol (PEG) or lysine.

6. The SHAL according to claim 1 or 2 , wherein the effector is DOTA or biotin.

7. A method of inhibiting the growth or proliferation of a cancer cell that expresses an HLA-DR10 marker, said method comprising: contacting said cancer with a selective high-affinity polydentate ligand (SHAL) according to claim 1 or 2 .

8. A method of detecting a cancer cell, said method comprising:

contacting said cancer cell with a chimeric molecule comprising an SHAL according to claim 1 or 2 attached to a detectable label; and

detecting the presence or absence of said detectable label.

9. The method of claim 8 , wherein said detectable label is selected from the group consisting of a gamma-emitter, a positron-emitter, an x-ray emitter, an alpha emitter, and a fluorescence-emitter.

10. A method of detecting a cancer cell, said method comprising:

contacting a cancer cell with a SHAL according to claim 1 or 2 attached to an epitope tag;

contacting said chimeric molecule with a chelate comprising a detectable moiety whereby said chelate binds to said epitope tag thereby associating said detectable moiety with said chelate; and

detecting said detectable moiety.

11. The method of claim 10 , wherein said detectable moiety comprises (i) a radionuclide, (ii) a detectable moiety selected from the group consisting of a gamma-emitter, a positron-emitter, an alpha emitter, an x-ray emitter and a fluorescence-emitter or (iii) a metal isotope selected from the group consisting of 99 Tc, 203 Pb, 67 Ga, 68 Ga, 72 As, 111 In 113m In, 97 Ru, 62 Cu, 641 Cu, 52 Fe, 52n Mn, 51 Cr, 186 Re, 188 Re, 77 As, 90 Y, 67 Cu, 169 Er, 121 Sn, 127 Te, 142 Pr, 143 Pr, 198 Au, 199 Au, 161 Tb, 109 Pd, 165 Dy, 149 Pm, 151 Pm, 153 Sm, 157 Gd, 159 Gd, 166 Ho, 172 Tm, 169 Yb, 175 Yb, 177 Lu, 105 Rh, and 111 Ag and said detecting comprises external imaging or internal imaging.